NCT01611077View on ClinicalTrials.gov

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions
Hypertension
Interventions
DRUG

Candesartan cilexetil

Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days

DRUG

Olmesartan medoxomil

Switch to olmesartan 40 mg tablets once daily for 42 days,

DRUG

Olmesartan/amlodipine

then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days

Trial Locations (11)

12043

Praxis Dr. Zemmrich, Berlin

26180

Praxis Dr. Loddo, Rastede

38836

Praxis Dr. Reimer, Anderbeck

45138

Praxis Dr. Koßler-Wiesweg, Essen

49661

St.-Josefs-Hospital, Cloppenburg

51429

Praxis Dr. Heinz, Bergisch Gladbach

65929

Praxis Dr. Rövenich, Frankfurt

67061

Praxis Dr. Pitule, Ludwigshafen

99510

Praxis Dr. Strzata, Kapellendorf

01129

Praxis Dr. Pohl, Dresden

04316

Praxis Dr. Paschmionka, Leipzig

All Listed Sponsors
lead

Institut für Pharmakologie und Präventive Medizin

NETWORK

NCT01611077 - Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg | Biotech Hunter | Biotech Hunter